Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Protective non-neutralizing SARS-CoV-2 monoclonal antibodies

Izadi, Arman LU and Nordenfelt, Pontus LU orcid (2024) In Trends in Immunology 45(8). p.609-624
Abstract

Recent studies show an important role for non-neutralizing anti-spike antibodies, including monoclonal antibodies (mAbs), in robustly protecting against SARS-CoV-2 infection. These mAbs use Fc-mediated functions such as complement activation, phagocytosis, and cellular cytotoxicity. There is an untapped potential for using non-neutralizing mAbs in durable antibody treatments; because of their available conserved epitopes, they may not be as sensitive to virus mutations as neutralizing mAbs. Here, we discuss evidence of non-neutralizing mAb-mediated protection against SARS-CoV-2 infection. We explore how non-neutralizing mAb Fc-mediated functions can be enhanced via novel antibody-engineering techniques. Important questions remain to be... (More)

Recent studies show an important role for non-neutralizing anti-spike antibodies, including monoclonal antibodies (mAbs), in robustly protecting against SARS-CoV-2 infection. These mAbs use Fc-mediated functions such as complement activation, phagocytosis, and cellular cytotoxicity. There is an untapped potential for using non-neutralizing mAbs in durable antibody treatments; because of their available conserved epitopes, they may not be as sensitive to virus mutations as neutralizing mAbs. Here, we discuss evidence of non-neutralizing mAb-mediated protection against SARS-CoV-2 infection. We explore how non-neutralizing mAb Fc-mediated functions can be enhanced via novel antibody-engineering techniques. Important questions remain to be answered regarding the characteristics of protective non-neutralizing mAbs, including the models and assays used for study, the risks of ensuing detrimental inflammation, as well as the durability and mechanisms of protection.

(Less)
Please use this url to cite or link to this publication:
author
and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Humans, SARS-CoV-2/immunology, Antibodies, Monoclonal/immunology, COVID-19/immunology, Antibodies, Viral/immunology, Animals, Antibodies, Neutralizing/immunology, Spike Glycoprotein, Coronavirus/immunology, Epitopes/immunology, Immunoglobulin Fc Fragments/immunology
in
Trends in Immunology
volume
45
issue
8
pages
609 - 624
publisher
Elsevier
external identifiers
  • pmid:39034185
  • scopus:85199048890
ISSN
1471-4981
DOI
10.1016/j.it.2024.06.003
language
English
LU publication?
yes
additional info
Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.
id
561fe88d-29b3-4a5f-8f01-98e6ed5bde30
date added to LUP
2024-08-20 10:13:24
date last changed
2025-07-10 10:54:13
@article{561fe88d-29b3-4a5f-8f01-98e6ed5bde30,
  abstract     = {{<p>Recent studies show an important role for non-neutralizing anti-spike antibodies, including monoclonal antibodies (mAbs), in robustly protecting against SARS-CoV-2 infection. These mAbs use Fc-mediated functions such as complement activation, phagocytosis, and cellular cytotoxicity. There is an untapped potential for using non-neutralizing mAbs in durable antibody treatments; because of their available conserved epitopes, they may not be as sensitive to virus mutations as neutralizing mAbs. Here, we discuss evidence of non-neutralizing mAb-mediated protection against SARS-CoV-2 infection. We explore how non-neutralizing mAb Fc-mediated functions can be enhanced via novel antibody-engineering techniques. Important questions remain to be answered regarding the characteristics of protective non-neutralizing mAbs, including the models and assays used for study, the risks of ensuing detrimental inflammation, as well as the durability and mechanisms of protection.</p>}},
  author       = {{Izadi, Arman and Nordenfelt, Pontus}},
  issn         = {{1471-4981}},
  keywords     = {{Humans; SARS-CoV-2/immunology; Antibodies, Monoclonal/immunology; COVID-19/immunology; Antibodies, Viral/immunology; Animals; Antibodies, Neutralizing/immunology; Spike Glycoprotein, Coronavirus/immunology; Epitopes/immunology; Immunoglobulin Fc Fragments/immunology}},
  language     = {{eng}},
  number       = {{8}},
  pages        = {{609--624}},
  publisher    = {{Elsevier}},
  series       = {{Trends in Immunology}},
  title        = {{Protective non-neutralizing SARS-CoV-2 monoclonal antibodies}},
  url          = {{http://dx.doi.org/10.1016/j.it.2024.06.003}},
  doi          = {{10.1016/j.it.2024.06.003}},
  volume       = {{45}},
  year         = {{2024}},
}